Forbes June 25, 2024
A phase 2 clinical trial of 231 patients with treatment-resistant depression found that the oral use of an extended-release tablet of ketamine could help prevent another depressive episode and is more effective and safer than the intravenous application of the medication. Patients reported side effects like headaches, dizziness, and anxiety.
While ketamine is more commonly used as an anesthetic medication, in the last twenty years, researchers have demonstrated its antidepressant properties, especially for patients who do not benefit from conventional anti-depressants like selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs). In most published studies, researchers administered ketamine to patients intravenously but because the medication gets absorbed a lot more rapidly in the bloodstream, it could cause...
Today's Sponsors
Today's Sponsor